Close

Lymphoma & Myeloma

Protocols

Lymphoma

HLHETCSPA

Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and cycloSPORINE


LYABVD

Treatment of Hodgkin's disease with DOXOrubicin, Bleomycin, vinBLAStine and Dacarbazine


LYALEM

Treatment with Subcutaneous or Intravenous Alemtuzumab for Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) or with Intravenous Alemtuzumab for Previously Untreated T-Prolymphocytic Leukemia (T-PLL)


ULYBEND

Treatment of Non-Hodgkin Lymphoma with Bendamustine


ULYBENDR

Treatment of Non-Hodgkin Lymphoma with Bendamustine and riTUXimab


ULYBRENTUX

Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma with Brentuximab


LYCARTOP

Summary for Topical Carmustine in Cutaneous T-cell Lymphoma


LYCCOP

Treatment of Hodgkin's disease using Cyclophosphamide, vinCRIStine, predniSONE


LYCDA

Treatment of Hairy Cell Leukemia with Cladribine


LYCHLOR

Therapy for Low Grade Lymphoma and Chronic Lymphocytic Leukemia Using Chlorambucil


​LYCHLRR

Treatment of Indolent B-cell Lymphoma and Chronic Lymphocytic Leukemia with Chlorambucil and riTUXimab


LYCHOP 

Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine and predniSONE


LYCHOPR

Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine, predniSONEand riTUXimab


LYCHOPRMTX

Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and RiTUXimab in Diffuse Large B-cell Lymphoma


​ULYCLLBEND

Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) with Bendamustine


LYCODOXMR 

Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vinCRIStine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and riTUXimab


LYCSPA

Cyclosporine for cytopenias associated with lymphoproliferative disorder of large granular lymphocytes 


​LYCVP 

Treatment of Advanced indolent lymphoma using Cyclophosphamide, vinCRIStine and predniSONE


LYCVPPABO

Treatment of Hodgkin's Disease with Cyclophosphamide, vinBLAStine, Procarbazine and predniSONE


​LYCVPR 

Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, vinCRIStine, predniSONE and riTUXimab (CVP-R)


LYCYCLO 

Therapy of Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia or Multiple Myeloma Using Cyclophosphamide


​LYFCR 

Treatment of Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and riTUXimab


​LYFLU 

Treatment of Low-Grade Lymphoma or Chronic Lymphocytic Leukemia with Fludarabine


LYFLUDR 

Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia and Relapsed Indolent Lymphoma with Fludarabine and riTUXimab


LYGDP 

Treatment of Lymphoma with Gemcitabine, Dexamethasone and CISplatin (GDP)


LYGDPR 

Treatment of Lymphoma with Gemcitabine, Dexamethasone and CISplatin (GDP) with riTUXimab


​LYHDMRP 

Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and riTUXimab


LYHDMTXP 

Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate


LYHDMTXR 

Treatment of Leptomeningeal Lymphoma or Recurrent Intracerebral Lymphoma with High Dose Methotrexate


LYIT 

Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine


​LYIVACR 

Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and riTUXimab


​ULYMFBEX 

Treatment for refractory cutaneous T-cell lymphoma using Bexarotene (Note: approval from the Health Canada Special Access Programme required)


​ULYMFECP 

Treatment of Cutaneous T-cell Lymphoma (Sézary syndrome) with Extracorporeal Photopheresis


LYPALL 

Lymphoma Palliative Chemotherapy


​ULYRICE 

Treatment of Advanced Stage Large B-Cell Non-Hodgkin’s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and riTUXimab


​LYRITUX 

Treatment of Lymphoma with single agent riTUXimab


​LYRMTN 

Maintenance riTUXimab for Indolent Lymphoma

Myeloma

UMYBORPRE 

Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone with or without Cyclophosphamide as Induction Pre-Stem Cell Transplant


UMYBORREL 

Treatment of Relapsed Multiple Myeloma Using Bortezomib, Dexamethasone with or without Cyclophosphamide


​UMYCTD 

Treatment of Systemic Light-chain (AL) Amyloidosis and Multiple Myeloma Using Cyclophosphamide, Thalidomide and Dexamethasone


​​MYHDC

Single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant


​UMYLENDEX

Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone


​UMYLENMTN 

Maintenance Therapy of Multiple Myeloma Using Lenalidomide


MYMP 

Treatment of Multiple Myeloma Using Melphalan and predniSONE


UMYMPBOR

Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan


​UMYMPT 

Treatment of Multiple Myeloma Using Melphalan, Prednisone and Thalidomide


MYPAM 

Treatment of Multiple Myeloma with Pamidronate


​​​UMYPOMDEX
  • Therapy of Multiple Myeloma Using Pomalidomide with Dexamethasone

  • ​UMYTHALID

    Therapy of Multiple Myeloma Using Thalidomide

    Terms of use

    The information contained in these documents is a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. 

    Use of these documents is at your own risk and is subject to the BC Cancer Agency's terms of use.

    Tab Heading
    Tab Heading
    SOURCE: Lymphoma & Myeloma ( )
    Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

    Copyright © BC Cancer Agency. All Rights Reserved.

      Copyright © 2015 Provincial Health Services Authority